Equillium, Inc. (EQ): Price and Financial Metrics

Equillium, Inc. (EQ): $2.49

0.01 (+0.40%)

POWR Rating

Component Grades













Add EQ to Watchlist
Sign Up

Industry: Biotech



in industry

EQ Stock Price Chart Interactive Chart >

Price chart for EQ

EQ Price/Volume Stats

Current price $2.49 52-week high $7.75
Prev. close $2.48 52-week low $1.82
Day low $1.82 Volume 66,600
Day high $2.55 Avg. volume 45,110
50-day MA $2.83 Dividend yield N/A
200-day MA $4.44 Market Cap 85.35M

Equillium, Inc. (EQ) Company Bio

Equillium Inc. is leveraging deep understanding of immunobiology to develop products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is based in La Jolla, California.

EQ Latest News Stream

Event/Time News Detail
Loading, please wait...

EQ Latest Social Stream

Loading social stream, please wait...

View Full EQ Social Stream

Latest EQ News From Around the Web

Below are the latest news stories about Equillium Inc that investors may wish to consider to help them evaluate EQ as an investment opportunity.

Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition

Equillium Inc (NASDAQ: EQ ), with only one asset in its pipeline , is expanding its drug development efforts via the acquisition of Bioniz Therapeutics . The deal, worth approximately $330 million, gives the biotech access to three therapeutics. Equillium will buy Bioniz in an all-stock deal for around 5.69 million shares and up to $57.5 million in development biobucks. The deal … Full story available on Benzinga.com

Benzinga | February 16, 2022

Equillium acquires Bioniz Therapeutics in all-stock deal

Equillium (EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront…

Seeking Alpha | February 16, 2022

Equillium Acquires Bioniz Therapeutics Significantly Expanding Pipeline of Novel Immunomodulatory Drug Candidates

LA JOLLA, Calif., February 16, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced that it has acquired Bioniz Therapeutics, Inc., a privately held clinical-stage biotechnology company. Bioniz developed its novel structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from its proprietary product discovery platform. T

Yahoo | February 16, 2022

Equillium Provides Timing Update on Conference Presentations

LA JOLLA, Calif., February 15, 2022--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders with high unmet medical need, today announced timing updates for two separate conference presentations.

Yahoo | February 15, 2022

Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight

Las Vegas, USA, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Systemic Lupus Erythematosus Pipeline Insights | Research Report 2022 by DelveInsight Systemic Lupus Erythematosus pipeline involves 70+ key companies continuously working towards developing 70+ Systemic Lupus Erythematosus treatment therapies, as per DelveInsight DelveInsight''s ‘ Systemic Lupus Erythematosus Pipeline Insight 2021'' report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the Systemic Lupus Erythematosus pipeline domain. Some of the essential takeaways from the Systemic Lupus Erythematosus Pipeline report: DelveInsight''s Systemic Lupus Erythemat...

Benzinga | February 9, 2022

Read More 'EQ' Stories Here

EQ Price Returns

1-mo -8.12%
3-mo -37.44%
6-mo -51.65%
1-year -62.04%
3-year -59.64%
5-year N/A
YTD -33.95%
2021 -29.53%
2020 58.28%
2019 -58.58%
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.4124 seconds.